ClinicalTrials.gg
CompletedNCT02477514Updated Aug 24, 2015

A Study to Evaluate the Effects of Tedizolid Phosphate on the Pharmacokinetics and Safety of Midazolam and Rosuvastatin (MK-1986-004)

A Phase 1 interventional study of midazolam and rosuvastatin in Skin Diseases, Bacterial, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-08-24.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
19 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to assess the effect of steady-state tedizolid phosphate on the single-dose pharmacokinetics of midazolam and rosuvastatin in healthy, adult participants.

02

Conditions studied

  • Skin Diseases, Bacterial
03

In context

Skin Diseases, Bacterial

37 studies on the registry are indexed under Skin Diseases, Bacterial; 2 are open to participants now.

This study's enrollment of 18 is below the median of 249 across 29 interventional studies indexed under Skin Diseases, Bacterial.

Browse Skin Diseases, Bacterial studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • healthy, adult males or females (women of non-)
  • continuous non-smokers who have not used nicotine-containing products for the previous 3 months

Exclusion criteria

Exclusion Criteria:

  • mentally or legally incapacitated or has significant emotional problems
  • history or presence of medical or psychiatric condition or disease
  • history or presence of alcoholism or drug abuse within the past 2 years
  • female participants who are pregnant, lactating, or of
  • donated blood or had significant blood loss within 56 days prior to first dose of study drug
  • plasma donation within 7 days prior to first dose of study drug
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Experimental Arm

    Day 1: participants will receive midazolam (2 mg); Day 3: participants will receive rosuvastatin (10 mg); Days 5-13: participants will receive tedizolid phosphate (200 mg); Day 14: participants will receive tedizolid phosphate (200 mg) plus midazolam (2 mg); Day 15: participants will receive tedizolid phosphate (200 mg); Day 16: participants will receive tedizolid phosphate (200 mg) plus rosuvastatin (10 mg); Day 17: participants will receive tedizolid phosphate (200 mg)

    Drug: midazolam · Drug: rosuvastatin · Drug: tedizolid phosphate

Interventions

  • 2 mg (1 mL of 2 mg/mL oral syrup) administered as a single dose on Days 1 and 14

  • 10 mg tablet administered as a single oral dose on Days 3 and 16

  • 200 mg oral tablet administered once daily on Days 5-17

06

What researchers measure

Primary outcomes

  1. Area under the concentration versus time curve, from 0 to last observed/measured non-zero concentration (AUC0-t) of midazolam alone or in combination with tedizolid phosphate

    Time frame: Days 1 and 14: pre-dose, 0.25, 0.5, 1, 1.5, 3, 4.5, 6, 8, 12, 24 hours

  2. AUC0-t of rosuvastatin alone or in combination with tedizolid phosphate

    Time frame: Days 3 and 16: pre-dose, 1, 3, 4, 5, 6, 8, 16, 24, 36, 48 hours

  3. Area under the concentration versus time curve from 0 to infinity (AUC0-inf) of midazolam alone or in combination with tedizolid phosphate

    Time frame: Days 1 and 14: pre-dose, 0.25, 0.5, 1, 1.5, 3, 4.5, 6, 8, 12, 24 hours

  4. AUC0-inf of rosuvastatin alone or in combination with tedizolid phosphate

    Time frame: Days 3 and 16: pre-dose, 1, 3, 4, 5, 6, 8, 16, 24, 36, 48 hours

  5. Maximum observed plasma concentration (Cmax) of midazolam alone or in combination with tedizolid phosphate

    Time frame: Days 1 and 14: pre-dose, 0.25, 0.5, 1, 1.5, 3, 4.5, 6, 8, 12, 24 hours

  6. Cmax of rosuvastatin alone or in combination with tedizolid phosphate

    Time frame: Days 3 and 16: pre-dose, 1, 3, 4, 5, 6, 8, 16, 24, 36, 48 hours

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2015, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2015
First posted
Jun 22, 2015
Start
Jun 2015
Primary completionActual
Aug 2015
CompletionActual
Aug 2015
Last update
Aug 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02477514
Responsible party
Sponsor
First posted
Jun 22, 2015
Start date
Jun 2015
Primary completion
Aug 2015
Completion
Aug 2015
Last update
Aug 24, 2015

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Midazolam · Rosuvastatin · Tedizolid phosphate

Start the discussion